ImClone and Bristol-Myers Squibb Announce ERBITUX Study Results

ImClone Systems and Bristol-Myers Squibb announced the results of several clinical studies of ERBITUX, an IgG1 monoclonal antibody, presented at the American Society of Clinical Oncology (ASCO) 41st Annual Meeting. "Clinical trial results observed in combinations of ERBITUX with widely used cancer treatments improve our understanding of where to focus our future study of this antibody," said Eric Rowinsky, M.D., ImClone Systems Chief Medical Officer. "Our long-term commitment to developing ERBITUX in multiple indications will include pivotal or exploratory studies of ERBITUX with other targeted therapies in colorectal, lung, pancreatic and ovarian cancers in addition to our ongoing Phase III studies with chemotherapy," he added. Data were presented from clinical studies exploring treatment of various stages of colorectal, head and neck, and ovarian cancers using ERBITUX either as a single agent or in combination with cytotoxic agents, including chemotherapy and radiation therapy. An article from TheStreet.com latest ebusiness news